PharmaShots | Incisive News in 3 Shots

Subscribe Now

Geographic Atrophy

Japan’s MHLW Receives NDA for Conditional Approval of Astellas’ Avacincaptad Pegol to Treat Geographic Atrophy

Japan’s MHLW Receives NDA for Conditional Approval of Astellas’ Avacincaptad Pegol to Treat Geographic Atrophy

February 5, 2025

Alkeus Pharmaceuticals Reports Topline Results from SAGA Trial of Gildeuretinol (ALK-001) for Geographic Atrophy Secondary to Age-Related Macular Degeneration

Alkeus Pharmaceuticals Reports Topline Results from SAGA Trial of Gildeuretinol (ALK-001) for Geographic Atrophy Secondary to Age-...

October 24, 2024

Insights+: The US FDA New Drug Approvals in August 2023

Insights+: The US FDA New Drug Approvals in August 2023

September 21, 2023

Iveric Bio Reports 24-Month Results of Izervay (avacincaptad pegol) for Geographic Atrophy

Iveric Bio Reports 24-Month Results of Izervay (avacincaptad pegol) for Geographic Atrophy

September 19, 2023

Iveric Bio Reports EMA Acceptance of MAA for Avacincaptad Pegol to Treat Geographic Atrophy

Iveric Bio Reports EMA Acceptance of MAA for Avacincaptad Pegol to Treat Geographic Atrophy

August 18, 2023

Iveric Bio's Izervay (avacincaptad pegol intravitreal solution) Receives the US FDA’s Approval for the Treatment of Geographic Atrophy

Iveric Bio's Izervay (avacincaptad pegol intravitreal solution) Receives the US FDA’s Approval for the Treatment of Geographic Atr...

August 7, 2023

Contact Us

First Floor, B-66, Sector 63 Noida, Uttar Pradesh, INDIA - 201301
+91-120 428 0707
connect@pharmashots.com
Newsletter

Our Information

Follow Us